Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Department of Medical Physics, McGill University Health Centre, Montreal, Canada.
Department of Radiation Oncology, Comprehensive Cancer Centre, Medical University of Vienna/General Hospital of Vienna, Vienna, Austria.
Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):1052-1062. doi: 10.1016/j.ijrobp.2019.12.019. Epub 2020 Jan 30.
The aim of this study was to investigate the influence of brachytherapy technique and applicator type on target dose, isodose surface volumes, and organ-at-risk (OAR) dose.
Nine hundred two patients treated with tandem/ovoids (T&O) (n = 299) and tandem/ring (T&R) (n = 603) applicators from 16 EMBRACE centers were analyzed. Patients received external beam radiation therapy and magnetic resonance imaging guided brachytherapy with dose prescription according to departmental practice. Centers were divided into 4 groups, according to applicator/technique: Ovoids and ring centers treating mainly with the intracavitary (IC) technique and ovoids and ring centers treating routinely with the intracavitary/interstitial (IC/IS) technique. V85Gy EQD2, CTV D (EQD2), and bladder, rectum, sigmoid, and vaginal 5-mm lateral-point doses (EQD2) were evaluated among center groups. Differences between T&O and T&R were tested with multivariable analysis.
For similar point A doses, mean CTV D was 3.3 Gy higher and V85Gy was 23% lower for ring-IC compared with ovoids-IC centers (at median target volumes). Mean bladder/rectum doses (D and ICRU-point) were 3.2 to 7.7 Gy smaller and vaginal 5-mm lateral-point was 19.6 Gy higher for ring-IC centers. Routine use of IC/IS technique resulted in increased target dose, whereas V85Gy was stable (T&R) or decreased (T&O); reduced bladder and rectum D and bladder ICRU-point by 3.5 to 5.0 Gy for ovoids centers; and similar OAR doses for ring centers. CTV D was 2.8 Gy higher, bladder D 4.3 Gy lower, rectovaginal ICRU-point 4.8 Gy lower, and vagina 5-mm lateral-point 22.4 Gy higher for ring-IC/IS versus ovoids-IC/IS centers. The P values were <.002 for all comparisons. Equivalently, significant differences were derived from the multivariable analysis.
T&R-IC applicators have better target dose and dose conformity than T&O-IC in this representative patient cohort. IC applicators fail to cover large target volumes, whereas routine application of IC/IS improves target and OAR dose considerably. Patients treated with T&R show a more favorable therapeutic ratio when evaluating target, bladder/rectum doses, and V85Gy. A comprehensive view on technique/applicators should furthermore include practical considerations and clinical outcome.
本研究旨在探讨近距离放疗技术和施源器类型对靶区剂量、等剂量表面体积和危及器官(OAR)剂量的影响。
分析了 16 个 EMBRACE 中心的 902 例接受 tandem/ovoids(T&O)(n=299)和 tandem/ring(T&R)(n=603)施源器治疗的患者。患者接受外照射放疗和磁共振成像引导的近距离放疗,剂量根据科室实践进行规定。根据施源器/技术,将中心分为 4 组:主要采用腔内(IC)技术治疗的 Ovoids 和 Ring 中心,以及常规采用腔内/间质(IC/IS)技术治疗的 Ovoids 和 Ring 中心。评估了中心组之间的点 A 剂量的 V85Gy EQD2、CTV D(EQD2)以及膀胱、直肠、乙状结肠和阴道 5mm 侧点剂量(EQD2)。使用多变量分析测试了 T&O 和 T&R 之间的差异。
对于相似的点 A 剂量,与 Ovoids-IC 中心相比,Ring-IC 中心的 CTV D 高 3.3Gy,V85Gy 低 23%(在中位数靶区体积下)。对于 Ring-IC 中心,膀胱/直肠剂量(D 和 ICRU 点)低 3.2 至 7.7Gy,阴道 5mm 侧点高 19.6Gy。常规使用 IC/IS 技术会导致靶区剂量增加,而 V85Gy 保持稳定(T&R)或降低(T&O);对于 Ovoids 中心,降低膀胱和直肠 D 以及膀胱 ICRU 点 3.5 至 5.0Gy;对于 Ring 中心,OAR 剂量相似。对于 Ring-IC/IS 中心,CTV D 高 2.8Gy,膀胱 D 低 4.3Gy,直肠阴道 ICRU 点低 4.8Gy,阴道 5mm 侧点高 22.4Gy。所有比较的 P 值均<0.002。同样,多变量分析也得出了显著差异。
在这个有代表性的患者队列中,T&R-IC 施源器的靶区剂量和剂量适形性优于 T&O-IC。IC 施源器无法覆盖大的靶区体积,而常规应用 IC/IS 则显著提高靶区和 OAR 剂量。当评估靶区、膀胱/直肠剂量和 V85Gy 时,接受 T&R 治疗的患者显示出更有利的治疗比。对技术/施源器的综合评估还应包括实际考虑因素和临床结果。